Streetbeat News

Regulatory

SWSS

Clean Energy Special Situations Corp. (SWSS) received a notice from Nasdaq for not complying with listing standards due to unpaid fees and failure to file its 2023 Form 10-K. The company plans to appeal the delisting decision and is exploring options to regain compliance. Trading of SWSS's common stock may be suspended on May 2, 2024, if the appeal to Nasdaq's Hearings Panel does not succeed.

Portfolio Pulse from Benzinga Newsdesk

April 29, 2024 | 8:08 pm

PFE

SGEN

The FDA has approved Seagen's Tivdak (tisotumab vedotin-tftv) for the treatment of cervical cancer, according to Bloomberg. This approval marks a significant milestone for Seagen in expanding its portfolio in cancer treatments. Pfizer (PFE), which may have been mentioned in the article, could be involved in this context due to partnerships or collaborations in the development or distribution of Tivdak.

Portfolio Pulse from Benzinga Newsdesk

April 29, 2024 | 7:53 pm

EIS

Israel has proposed a 40-day ceasefire to Hamas in Gaza for the release of captives, reducing the number of hostages for release to 33. Concerns rise over potential ICC arrest warrants for Israeli officials, including Prime Minister Netanyahu, which could jeopardize the ceasefire agreement. U.S. Secretary of State Antony Blinken is touring the Middle East, emphasizing the importance of Hamas accepting Israel's ceasefire offer to halt the offensive in Gaza. The iShares MSCI Israel ETF (EIS) saw a 0.9% increase.

Portfolio Pulse from Piero Cingari

April 29, 2024 | 7:51 pm

CCJ

SPY

VGK

The White House is considering a ban on imports of Russian uranium as a House bill targeting the same issue stalls. Discussions are ongoing about prohibiting Russian reactor fuel imports, which could have significant implications for energy and national security policies.

Portfolio Pulse from Benzinga Newsdesk

April 29, 2024 | 7:24 pm

TENX

Tenax Therapeutics is set to be issued a U.S. patent for 'LEVOSIMENDAN FOR TREATING PULMONARY HYPERTENSION WITH HEART FAILURE WITH PRESERVED EJECTION FRACTION', marking a significant milestone in its efforts to address this medical condition.

Portfolio Pulse from Benzinga Newsdesk

April 29, 2024 | 7:15 pm

DGX

Quest Diagnostics shares are trading higher following the FDA's finalization of rules to regulate lab-developed tests similarly to other diagnostics. This regulatory change is seen as a positive development for the company.

Portfolio Pulse from Benzinga Newsdesk

April 29, 2024 | 7:12 pm

META

SNAP

TikTok's parent company, ByteDance, opts to fight a potential U.S. ban in court rather than sell its assets, as mandated by a new bill signed by President Biden. The bill, which received bipartisan support, could force ByteDance to sell TikTok's U.S. operations within 9-12 months to avoid a ban. This situation benefits competitors like Meta Platforms Inc (META) and Snap Inc (SNAP), with Meta recently losing value due to poor quarterly results, while Snap's shares surged after a positive earnings report. TikTok CEO Shou Chew emphasizes the fight for freedom of expression and plans to challenge the ban's constitutionality, highlighting the national security versus First Amendment debate.

Portfolio Pulse from Natan Ponieman

April 29, 2024 | 6:40 pm

BIDU

IWM

TSLA

U.S. stocks opened positively, with major indices rising ahead of key events including tech earnings, a Federal Reserve meeting, and the April jobs report. Tesla surged 16% on a partnership with Baidu for its Full Self-Driving system in China. Small caps outperformed, and the iShares Russell 2000 ETF rose 0.9%. The Bank of Japan intervened to support the yen, causing a significant forex market movement. Natural gas prices jumped 7%, while Bitcoin saw a decline. Sector-wise, consumer discretionary and utilities stocks led gains.

Portfolio Pulse from Piero Cingari

April 29, 2024 | 6:14 pm

ANVS

Annovis Bio Inc (NASDAQ:ANVS) shares plummeted after releasing Phase 2/3 study data for buntanetap in Alzheimer's patients, showing no statistically significant difference in ADCS-CGIC scores and a large placebo effect in ADCS-ADL scores. However, improvements were observed in ADAS-Cog 11 scores, indicating a potential symptomatic effect with a disease-modification trend. The company plans to discuss the data with the FDA and proceed to a next Phase 3 study.

Portfolio Pulse from Vandana Singh

April 29, 2024 | 5:53 pm

KBE

KRE

SPY

XLF

Bank regulators are scheduled to testify before Congress in May, an event that could influence perceptions and policies affecting the banking sector. This testimony is particularly significant for investors in banking and financial sector ETFs and stocks, as it may impact regulatory and market conditions.

Portfolio Pulse from Benzinga Newsdesk

April 29, 2024 | 5:51 pm